New updates on berotralstat and navenibart from manufacturer
The pharmaceutical company behind berotralstat (Orladeyo) and the potential HAE medicine navenibart shared an update on its business with the HAE community.
The update showed that the company has started to distribute a new oral pellet formulation of berotralstat, which is licensed by the US FDA for children living with HAE. A new pharmacy partner in the US has also been confirmed, while enrollment of patients into a trial of navenibart has been completed.
Charlie Gayer, President and Chief Executive Officer of BioCryst, said: “We are especially excited to have begun shipments of the berotralstat oral pellet formulation – an important milestone for children living with hereditary angioedema – and we are fully committed to making the launch a success.”
The following detailed updates were provided:
- BioCryst has engaged CareMed to serve as its new commercial pharmacy partner in the United States. CareMed is a full-service specialty pharmacy that provides expert care to patients living with rare diseases, and will become the sole source specialty pharmacy for berotralstat shipments to patients beginning in Q3 2026.
- Initial product shipments of berotralstat oral pellets to patients began the week of 3 August 2026, marking a new paradigm in the treatment of HAE in children.
- Patient enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart in hereditary angioedema, was completed in June. Navenibart is being studied with every three-month and every six-month subcutaneous dosing. The program remains on track to report top-line results from both doses in Q3 2027.
(Source: BioCryst)








